J&J's diabetes unit attracts Chinese buyers, Novartis and Biocon form a biosimilar deal, plus Keytruda-Lenvima combo gets a breakthrough tag.
Sick of dealing with generic drug shortages and price increases, five large U.S. health systems are forming their own drugmaker.
Analysts previously signaled that market share for Allergan’s Botox should be safe after competitors show up. But a new survey indicates otherwise.
Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Amgen hopes 2018 is the year Kyprolis lives up to its sales potential, and it's starting the year with a pair of positive updates.
Novartis and Biocon, which have each had success developing biosimilars on their own, will now see what they can do together.
Actor Anthony Anderson is a comedian, but when it comes to diabetes, he is a serious advocate.
As CEO Emma Walmsley remakes the company's approach in emerging markets, GlaxoSmithKline will cut jobs in sub-Saharan Africa and rely on distributors.
Valeant and Pershing Square are one step closer to putting years of insider trading allegations in the past.
Pfizer is facing tough competition with Xalkori, and the latest move from England’s cost watchdogs isn’t making things any easier.